2cureX (2CUREX) H1 2025 earnings summary

Executive summary

• H1 2025 marked by execution of a new strategy, validation of the direct-to-patient model, and expansion through partnerships and automation.

• IndiTreat® accessed directly by patients in the UK, Sweden, and Germany, confirming market demand for precision oncology.

• Strategic partnership with PreComb enables pharma collaborations and clinical trials in multiple cancer types.

• AI-driven workflows and automation have improved operational efficiency and scalability.

• Investor support remains strong, with ongoing capital and strategic input from key stakeholders.

Financial highlights

• Net sales for H1 2025 reached 25 KSEK, compared to 0 KSEK in H1 2024.

• Profit before tax improved to -1,951 KSEK from -9,560 KSEK year-over-year, reflecting reduced operational costs.

• Cash and cash equivalents increased to 5,098 KSEK as of June 30, 2025, up from 3,130 KSEK a year earlier.

• Equity ratio declined to 12% from 40% year-over-year.

• Cash flow for H1 2025 was -42 KSEK, compared to 15 KSEK in H1 2024.

Outlook and guidance

• Plans to scale the direct-to-patient model in the UK, Sweden, Denmark, and Germany.

• Focus on delivering pharma collaborations via the PreComb partnership and supporting CE-IVDR regulatory milestones.

• Continued integration of AI and automation to drive efficiency and growth.

• Strengthening leadership team and exploring acquisitions to accelerate expansion.